keyword
MENU ▼
Read by QxMD icon Read
search

Secukinumab

keyword
https://www.readbyqxmd.com/read/29334270/secukinumab-in-multi-failure-psoriatic-patients-the-last-hope
#1
M Magnano, C Loi, A Patrizi, P Sgubbi, R Balestri, G Rech, L Tasin, C R Girardelli, A Conti, G Odorici, A Campanati, A M Offidani, F Bardazzi
Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent, and, in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also those agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, recently approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis...
January 15, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29332708/management-of-psoriasis-in-patients-with-inflammatory-bowel-disease-from-the-medical-board-of-the-national-psoriasis-foundation
#2
REVIEW
Scott M Whitlock, Clinton W Enos, April W Armstrong, Alice Gottlieb, Richard G Langley, Mark Lebwohl, Joseph F Merola, Caitriona Ryan, Michael P Siegel, Jeffrey M Weinberg, Jashin J Wu, Abby S Van Voorhees
BACKGROUND: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017...
February 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29323542/the-comparative-efficacy-of-brodalumab-in-patients-with-moderate-to-severe-psoriasis-a-systematic-literature-review-and-network-meta-analysis
#3
Laura Sawyer, Iain Fotheringham, Emily Wright, Najeeda Yasmeen, Carl Gibbons, Anders Holmen Møller
PURPOSE: To evaluate the relative efficacy of brodalumab compared with approved biologic therapies and apremilast for moderate-to-severe psoriasis. METHODS: We searched MEDLINE, Embase and Cochrane for randomized controlled trials reporting induction phase responses. The primary analysis examined the proportion of patients achieving Psoriasis Area Severity Index (PASI) 50, 75, 90 or 100 responses using a random-effects Bayesian multinomial likelihood model with probit link, with and without adjustment for variation in study-level placebo responses...
January 11, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29307635/efficacy-and-safety-of-switching-to-ixekizumab-in-secukinumab-non-responders-with-plaque-psoriasis-a-multicenter-retrospective-study-of-interleukin-il-17a-antagonist-therapies
#4
Jorge R Georgakopoulos, Michelle Phung, Arvin Ighani, Jensen Yeung
No abstract text is available yet for this article.
January 4, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29299984/biologic-therapy-in-psoriasis-part-ii-efficacy-and-safety-of-new-treatment-targeting-il23-il-17-pathways
#5
E Molinelli, A Campanati, Giulia Ganzetti, V Brisigotti, A Offidani
BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis. METHODS: Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab). RESULTS: In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine...
January 3, 2018: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29298315/biologicals-and-small-molecules-in-psoriasis-a-systematic-review-of-economic-evaluations
#6
Christian Kromer, Daniel Celis, Diana Sonntag, Wiebke K Peitsch
Biological therapy for moderate-to-severe psoriasis is highly effective but cost-intensive. This systematic review aimed at analyzing evidence on the cost-effectiveness of biological treatment of moderate-to-severe psoriasis. A literature search was conducted until 30/06/2017 in PubMed, Cochrane Library, LILACS, and EconLit. The quality of identified studies was assessed with the checklist by the Centre for Reviews and Dissemination guidance. Out of 482 records, 53 publications were eligible for inclusion. Half of the studies met between 20 and 25 of the quality checklist items, displaying moderate quality...
2018: PloS One
https://www.readbyqxmd.com/read/29290076/risk-of-serious-infections-in-biological-treatment-of-patients-with-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-a-meta-analysis
#7
Sen Wang, Qian He, Zongwen Shuai
The objective of the study is to quantitatively assess the risk of serious infections in patients with axial spondyloarthritis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) treated by biologics enrolled in randomized controlled trials (RCTs). A systematic literature searches of MEDLINE (via PubMed), EMBASE, the Cochrane Library and abstracts archives of the annual scientific meetings of both the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) was conducted through October 2015...
December 30, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29285605/comparative-effectiveness-of-abatacept-apremilast-secukinumab-and-ustekinumab-treatment-of-psoriatic-arthritis-a-systematic-review-and-network-meta-analysis
#8
REVIEW
P Kawalec, P Holko, P Moćko, A Pilc
To assess the comparative effectiveness and safety of novel biologic therapies in psoriatic arthritis (PsA) and to establish the position of the non-anti-tumor necrosis factor α (TNF-α) biologic drugs in the treatment regimen of the disease. A systematic review and network meta-analysis (NMA) was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) requirements. Two investigators identified the studies, abstracted data, and assessed the risk of bias independently...
December 28, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29278210/biologics-in-inflammatory-and-immunomediated-arthritis
#9
Michele Maria Luchetti, Devis Benfaremo, Armando Gabrielli
BACKGROUND: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis. METHODS: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases...
December 26, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29273067/efficacy-safety-and-tolerability-of-secukinumab-in-patients-with-active-ankylosing-spondylitis-a-randomized-double-blind-phase-3-study-measure-3
#10
Karel Pavelka, Alan Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie, Brian Porter
BACKGROUND: Secukinumab, an anti-interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 150 mg subcutaneous maintenance dosing, following an intravenous loading regimen. METHODS: A total of 226 patients were randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 300 mg (IV-300 mg) or 150 mg (IV-150 mg) every 4 weeks, or matched placebo...
December 22, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29249053/a-review-of-switching-biologic-agents-in-the-treatment-of-moderate-to-severe-plaque-psoriasis
#11
REVIEW
Yifan Hu, Zeyu Chen, Yu Gong, Yuling Shi
Psoriasis is an immune-mediated polygenic inherited skin disease. Many biologic agents have been approved for the treatment of moderate-to-severe plaque psoriasis. The most commonly utilized biologics include TNF-α antagonists (etanercept, infliximab, and adalimumab), IL-12/23P40 antagonist (ustekinumab), IL-23P19 antagonist (guselkumab), IL-17A antagonist (secukinumab and ixekizumab), and IL-17RA antagonist (brodalumab). However, some patients may fail to respond well to their first biologic agent. Reasons for failure include primary failure (lack of initial efficacy), secondary failure (loss of efficacy over time) or the development of adverse effects...
December 16, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29248520/new-therapies-for-atopic-dermatitis-additional-treatment-classes
#12
Paras P Vakharia, Jonathan I Silverberg
BACKGROUND: A wide array of miscellaneous agents is being studied for the treatment of atopic dermatitis (AD), including targeted topical, oral systemic and biologic agents. OBJECTIVE: To review the known efficacy and safety to-date for such agents being studied for the treatment of AD. METHODS: A non-systematic review of the literature was performed. PubMed and ClinicalTrials.gov were searched for studies assessing agents not described in previous chapters for the treatment of AD...
December 14, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29244162/efficacy-and-safety-of-biologics-targeting-interleukin-6-12-23-and-17-pathways-for-peripheral-psoriatic-arthritis-a-network-meta-analysis
#13
Dongze Wu, Jiang Yue, Lai-Shan Tam
Objective: To investigate the comparative efficacy, safety and tolerability of IL-6, IL-12/23 and IL-17 inhibitors for patients with active PsA. Methods: Randomized controlled trials evaluating the efficacy, safety and tolerability of IL-6, IL-12/23 and IL-17 inhibitors were identified by a comprehensive systematic literature review. Pairwise meta-analyses and Bayesian network meta-analyses using the random effects model were performed to estimate pooled odds ratios (ORs) and 95% credible intervals of attaining a 20% or 50% improvement in ACR criteria (ACR20 and ACR50, respectively) across trials...
December 13, 2017: Rheumatology
https://www.readbyqxmd.com/read/29226369/safety-of-biologics-in-psoriasis
#14
REVIEW
Masahiro Kamata, Yayoi Tada
The advent of biologics brought a paradigm shift in ways to treat psoriatic patients because they have dramatic efficacy. At the same time, safety concerns about biologics have been raised. In this paper, we focus on the safety profile of biologics for psoriasis. As of 2017, six biologics are available in Japan. Two tumor necrosis factor-α inhibitors; infliximab and adalimumab, one anti-interleukin (IL)-12/23p40 antibody; ustekinumab, and IL-17 inhibitors; secukinumab, ixekizumab and brodalumab. Secukinumab and ixekizumab are anti-IL-17A antibodies...
December 10, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/29218492/efficacy-of-secukinumab-in-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-the-north-american-subgroup-of-patients-pooled-analysis-of-four-phase-3-studies
#15
David Pariser, Ellen Frankel, Joel Schlessinger, Yves Poulin, Ronald Vender, Richard G Langley, Xiangyi Meng, Adriana Guana, Judit Nyirady
INTRODUCTION: Demographic and disease characteristics may impact response to psoriasis therapies. The objective of this study is to explore the safety and efficacy profile of secukinumab in North American (NA) versus non-NA patients with moderate to severe psoriasis. METHODS: Data were pooled from four phase 3 studies of secukinumab. Secukinumab (300 and 150 mg) was administered at baseline, weeks 1, 2, and 3, then every 4 weeks from week 4 to 48. RESULTS: Peak efficacy was observed at week 16 in NA and non-NA patients with secukinumab 300 mg and secukinumab 150 mg, and disease clearance was maintained to week 52...
December 7, 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/29194723/long-term-clinical-efficacy-and-safety-of-secukinumab-for-japanese-patients-with-psoriasis-a-single-center-experience
#16
Mami Momose, Akihiko Asahina, Yoshinori Umezawa, Hidemi Nakagawa
Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin-17A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study is to assess long-term efficacy and safety of secukinumab for 52 weeks in real-world clinical practise in our facility. A total of 83 patients (71 with psoriasis vulgaris and 12 with psoriatic arthritis) were included, and 49 of them were bio-switched patients. Psoriasis Area and Severity Index (PASI) 75 and PASI-90 responses were 80% and 64% at week 12, 77% and 65% at week 24, and 76% and 58% at week 52, respectively...
November 30, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/29188733/investigational-drugs-in-clinical-trials-for-hidradenitis-suppurativa
#17
Peter Theut Riis, Linnea R Thorlacius, Gregor B Jemec
Hidradenitis suppurativa is a chronic skin disease with a significant unmet need for treatment options. Randomized controlled trials are few and only a single drug (adalimumab) has Hidradenitis as a registered indication. Areas covered: The clinicaltrials.gov and the EudraCT clinical trials register for reported trials on Hidradenitis Suppurativa was searched on the 22-06-2017. Trials for upcoming new drugs for HS are reported focusing on drugs in phase I and II trials. Expert opinion: Currently, MABp1, Secukinumab, CJM112, Apremilast and IFX-1 are being investigated in Phase I and II trials and offer theoretical and promising new treatment options...
December 4, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29180095/drug-survival-of-secukinumab-in-real-world-plaque-psoriasis-patients-a-52-week-multicenter-retrospective-study
#18
Jorge R Georgakopoulos, Arvin Ighani, Michelle Phung, Jensen Yeung
No abstract text is available yet for this article.
November 24, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29171861/matching-adjusted-indirect-comparison-of-efficacy-in-patients-with-moderate-to-severe-plaque-psoriasis-treated-with-ixekizumab-versus-secukinumab
#19
R B Warren, A Brnabic, Daniel Saure, R G Langley, K See, J J Wu, A Schacht, L Mallbris, A Nast
BACKGROUND: Head-to-head randomised studies comparing ixekizumab and secukinumab in the treatment of psoriasis are not available. OBJECTIVE: Assess efficacy and quality of life with ixekizumab vs. secukinumab treatment using matching-adjusted indirect comparisons. METHODS: Psoriasis Area and Severity Index (PASI) improvement of at least 75%, 90% and 100% and Dermatology Life Quality Index (DLQI) 0/1 response rates for approved doses of ixekizumab (160 mg at Week 0, then 80 mg every two weeks for the first 12 weeks) and secukinumab (300 mg at Weeks 0, 1, 2, 3 and 4, then 300 mg every 4 weeks) treatment were compared using data from active (etanercept and ustekinumab) and placebo-controlled studies...
November 24, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29169562/response-to-secukinumab-after-treatment-failure-with-ustekinumab-in-6-patients-with-plaque-psoriasis
#20
D Morgado-Carrasco, J Riera-Monroig, X Fustà-Novell, M Alsina Gibert
No abstract text is available yet for this article.
November 20, 2017: Actas Dermo-sifiliográficas
keyword
keyword
30575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"